Search database
Filter
196
Text search: FDC
Featured
Language
Document type
135
27
17
7
5
2
1
1
1
Countries
15
10
10
8
6
5
5
5
5
4
4
4
4
4
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
17
13
11
8
6
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
Category
109
34
6
5
3
2
Toolboxes
60
14
11
8
3
3
2
2
1
1
1
1

Tuberculosis control in prisons

A. Bone; A. Aerts, M. Grzemska World Health Organization; International commitee of the Red Cross (2000) C_WHO
A manual for programme managers. БОРЬБА С ТУБЕРКУЛЕЗОМ В ТЮРЬМАХ Руководство для руководителей программ
NOVEMBER 2012 This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘ ... more
The END TB Strategy
Vol. 2: Clinicians' Guide
Clinicians’ Guide is designed to assist busy medical practitioners in the field with patient management by providing current, essential, practical guidance and background, packaged into a single resource
Reducing the humanitarian impact of the use of explosive weapons in populated areas is a key priority for the United Nations, the International Committee of the Red Cross (ICRC), civil society and an increasing number of Member States. The United Nations Secretary-General has expressly called on ... more
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.

Medicines Catalog August 2018

Global Drug Facility World Health Organization WHO, Stop TB (2018) C_WHO
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ... more
1st edition This resource provides practical guidance for front line health workers responsible for the diagnosis, management and care of patients with these two diseases. Published in collaboration with the World Diabetes Foundation
L’étude a pour objectif général de faire une analyse de la santé communautaire au Burkina Faso et spécifiquement de : 1) décrire la nature et le processus de développement des SBC; 2) déterminer les forces et les faiblesses des documents d’orientation des SBC; 3) documenter les bonnes pr ... more
The Global Antibiotic Resistance Partnership (GARP)-Mozambique team, in partnership with the Center for Disease Dynamics, Economics & Policy (CDDEP), has produced this report as part of a solid com-mitment to develop actionable policy proposals to tackle antibiotic resistance and improve appropriate ... more
PlosOne January 20, 2021 https://doi.org/10.1371/journal.pone.0241899 Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antim ... more
The Coronavirus is spreading globally. How can individuals, communities and humanitarian actors best respond to the COVID-19 outbreak? How can the Sphere Handbook guide our response? This document has two sections: A. The first section covers fundamental principles which are crucial to a succe ... more
FDA’s compounding program aims to protect patients from unsafe, ineffective and poor quality compounded drugs, while preserving access to lawfully-marketed compounded drugs for patients who have a medical need for them. Here you can find informations to laws &policies, compliance action, ....
- A Skills Building Program for Clinicians and Non-Clinicians. Adherence guidelines- slide deck- training course for health providers
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr ... more